A preprint from Insilico Medicine outlines a dual-purpose AI-driven workflow aimed at revolutionizing drug discovery. This initiative addresses two critical challenges: efficiently navigating the vast chemical space of over 10⁶⁰ potential drug molecules and safeguarding against competitors developing similar drugs. The workflow, named LEGION—an acronym for Latent Enumeration, Generation, Integration, Optimization, and Navigation—was applied to the NLRP3 protein, a target for Insilico’s oral inhibitor ISM8969, which is in the pipeline for treating Parkinson’s disease.
Insilico’s approach not only seeks to streamline the discovery process but also aims to fortify intellectual property (IP) positions by generating and publicly disclosing a substantial number of molecular structures. By releasing over 120 million NLRP3-related molecules, Insilico intends to create barriers for competitors attempting to patent similar compounds, effectively closing off common scaffold-hopping strategies. The implications of this strategy are significant, as it could redefine competitive dynamics in the pharmaceutical landscape, particularly for high-potential targets like NLRP3, which may rival the lucrative GLP-1 market in the future.
Get started today with Solo access →
